Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.65 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.65 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | XIAP | P98170 | 1/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28554624 | 1.00 | SLC1A3 (0.65) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| SCHEMBL2587284 | 1.00 | SLC1A3 (0.65) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| SCHEMBL15835402 | 1.00 | SLC1A3 (0.65) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| SCHEMBL30963017 | 1.00 | SLC1A3 (0.65) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| SCHEMBL30963023 | 0.85 | SLC1A3 (0.47) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| SCHEMBL23521343 | 0.83 | GRIA2 (0.56) | SLC1A3SLC1A2SLC1A1CYP2D6SLC7A5 | |
| D-Phenylalanine SCHEMBL1537167 | 0.83 | SLC7A5 (0.69) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| Phenylalanine SCHEMBL528154 | 0.83 | SLC7A5 (0.69) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| D-Phenylalanine SCHEMBL1537464 | 0.83 | SLC7A5 (0.69) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI | |
| Phenylalanine SCHEMBL1537266 | 0.83 | SLC7A5 (0.69) | SLC1A3SLC1A2SLC1A1CYP2D6ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533023-B2 | EIF4E binding peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-01-03 | — | — | US | disclosed |
| EP-2569327-B1 | EIF4E BINDING PEPTIDES | AGENCY SCIENCE TECH & RES (SG) | 2016-05-25 | — | — | EP | disclosed |
| US-9278993-B2 | Cell-targeting nanoparticles and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-03-08 | — | — | US | disclosed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | disclosed |
| US-20160038567-A1 | EIF4E BINDING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-11 | — | — | US | disclosed |
| EP-2976354-A1 | STAPLING eIF4E INTERACTING PEPTIDES | Agency For Science, Technology And Research (SG) | 2016-01-27 | — | — | EP | disclosed |
| CN-105263950-A | Stapling eif4e interacting peptides | AGENCY SCIENCE TECH & RES | 2016-01-20 | — | — | CN | disclosed |
| US-9018348-B2 | eIF4E binding peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-04-28 | — | — | US | disclosed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | disclosed |
| US-20130130989-A1 | EIF4E BINDING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-05-23 | — | — | US | disclosed |
| EP-1750740-A1 | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING LANTIBIOTIC CONTAINING COMPOSITIONS | MOLICHEM MEDICINES, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005115432-A2 | TREATMENT OF OCULAR DISEASES AND DISORDERS USING LANTIBIOTIC COMPOSITIONS | MOLICHEM MEDICINES, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005107787-A1 | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING LANTIBIOTIC CONTAINING COMPOSITIONS | MOLICHEM MEDICINES, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250681-A1 | Treatment of ocular diseases and disorders using lantibiotic compositions | MOLICHEM MEDICINES, INC. (US) | 2005-11-10 | — | — | US | disclosed |
| US-20050250682-A1 | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions | MOLICHEM MEDICINES, INC. (US) | 2005-11-10 | — | — | US | disclosed |
| EP-0973540-B1 | ISOLATION AND STRUCTURAL ELUCIDATION OF THE CYTOSTATIC LINEAR AND CYCLO-DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18 | UNIV ARIZONA (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-0973540-A4 | ISOLATION AND STRUCTURAL ELUCIDATION OF THE CYTOSTATIC LINEAR AND CYCLO-DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18 | UNIV ARIZONA (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6239104-B1 | ISOLATED AND PURIFIED SUBSTANCE WHICH INHIBITS NEOPLASTIC CELL GROWTH DENOMINATED DOLASTATIN 16 | ARIZONA BOARD OF REGENTS | 2001-05-29 | — | — | US | disclosed |
| EP-0973540-A1 | ISOLATION AND STRUCTURAL ELUCIDATION OF THE CYTOSTATIC LINEAR AND CYCLO-DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18 | ARIZONA BOARD OF REGENTS (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998036765-A1 | ISOLATION AND STRUCTURAL ELUCIDATION OF THE CYTOSTATIC LINEAR AND CYCLO-DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18 | ARIZONA BOARD OF REGENTS (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250681-A1 | Treatment of ocular diseases and disorders using lantibiotic compositions | LPXN, EYA3, EYA2 | SLC1A3 1058/4885SLC1A2 1434/4885SLC1A1 1647/4885 |
| US-20050250682-A1 | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions | PKD2, DDR1, PKD1 | SLC1A3 3208/4885SLC1A2 2950/4885SLC1A1 2656/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | SLC1A3 2637/4885SLC1A2 3708/4885SLC1A1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.